FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 456 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients... September 10, 2025 Spotlight On: Pelvic Physical Therapists in Cancer Care March 31, 2021 Tailored Psychotherapy Eases Depression in People with Advanced Cancer August 9, 2018 For Women with Breast Cancer, Regular Exercise May Improve Survival May 15, 2020 Load more HOT NEWS FDA Approves Tepotinib for Metastatic Non-Small Cell Lung Cancer Survivorship and Immune Checkpoint Inhibitors The long road to targeting the holy grail of the immune... Four Different Doctors Misdiagnosed Woman’s Breast Pain Because “Breast Cancer Doesn’t...
